Skip to main content
. 2023 Jun 7;15(6):e40100. doi: 10.7759/cureus.40100

Figure 1. Faricimab in a patient with refractory neovascular age-related macular degeneration.

Figure 1

An 89-year-old man with 12 months on bevacizumab followed by 38 months of aflibercept treatment showed persistent subretinal fluid (SRF) in the right eye (A). Optical coherence tomography images one month (B), two months (C), and four months (D) after monthly faricimab injection showed a reduction of central subfield thickness and resolution of SRF.